SP-0383: Update on HIOB Trial: hypofractionated WBI plus intraoperative boost (IOERT) in early stage breast cancer
نویسندگان
چکیده
منابع مشابه
Intraoperative radiotherapy (IORT) as boost in breast cancer
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show huge differences in dose delivery and coverage of the tissue at risk. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments (IOERT) with single doses around 10 Gy. At median follow-up periods at 6 years, outstandingly low local ...
متن کاملBoost IORT in Breast Cancer: Body of Evidence
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show decisive differences in dose delivery. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments with single doses around 10 Gy, providing outstandingly low local recurrence rates in any risk constellation also at long term analyses...
متن کاملEarly stage breast cancer and radiotherapy: update.
Breast cancer (BC) is the most common malignancy among women. Therapeutic options are based on disease staging, histopathological characteristics, age, and others. The objective of the present study is to carry out an update of the concepts and definitions of radiotherapy (RT) in conservative treatment of early-stage breast cancer, with emphasis on indications, contraindications, RT dose fracti...
متن کاملIntraoperative boost radiation effects on early wound complications in breast cancer patients undergoing breast-conserving surgery
Background/aim: Intraoperative radiation therapy (IORT) may pose a risk for wound complications. All technical aspects of IORT regarding early wound complications were evaluated. Materials and methods: Ninety-three consecutive patients operated on with the same surgical technique and given (study group) or not given (control group) IORT were included. Wound complications were evaluated in two g...
متن کاملPhase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results
BACKGROUND To report toxicity and early clinical outcomes of hypofractionated simultaneous integrated boost (SIB) approach with Volumetric Modulated Arc Therapy (VMAT) as adjuvant treatment after breast-conserving surgery. METHODS Patients presenting early-stage breast cancer were enrolled in a phase II trial. ELIGIBILITY CRITERIA age > 18 years old, invasive cancer or ductal carcinoma in s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2013
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(15)32689-x